Les Meilleures Cliniques et Coûts d'immunologie en 2026 en Italie

Advanced cancer immunotherapies like CAR T-cell therapy are available in Italy. The Italian Medicines Agency (AIFA) authorizes these treatments for specific blood cancers. Leading centers in Milan and Rome provide clinical access. Specialized facilities like San Raffaele also offer advanced gene therapies.

• Authorized conditions: Treatment is available for B-cell leukemia and certain lymphomas.
• Reimbursement status: The National Health Service covers costs for eligible patients.
• Specialized centers: San Raffaele and Humanitas Research Hospital provide high-specialization care.
• Expert access: Dr. Alessandro Aiuti leads advanced gene therapy research at San Raffaele.

Bookimed Expert Insight: Milan has become the primary hub for Italian immunotherapy. Clinics like San Raffaele combine research with clinical care, serving 300,000 patients annually. Our data shows these IRCCS-accredited centers often manage the highest volume of complex immune cases. Patients should target these large research hospitals to find the widest range of active clinical trials.

Patient Consensus: Patients note that while treatment is highly effective for blood cancers, the approval process can take three months. It is important to prepare for travel to major northern hubs like Milan because specialized care is rarely available at smaller local hospitals.

San Raffaele Hospital and Humanitas Research Hospital in Milan are globally recognized for treating rare immune disorders. San Raffaele pioneered the world first stem cell gene therapy for ADA-SCID. These centers hold IRCCS accreditation. This status marks them as premier Italian research institutes for molecular medicine.

• San Raffaele expertise: Offers specialized treatment for genetic diseases and rare immune system disorders.
• Clinical pioneers: Dr. Alessandro Aiuti leads units performing gene therapy for Wiskott-Aldrich Syndrome.
• Global recognition: Dr. Emanuele Della Torre is a world expert in IgG4-related disease.
• Research status: Humanitas Research Hospital is JCI-accredited and ranked among top 10% research institutions.

Bookimed Expert Insight: Data shows that Milan is the primary hub for rare immunology. Clinics like San Raffaele and San Donato serve 300,000 patients yearly. Their IRCCS status is a key quality signal. This accreditation means they receive direct government funding for advanced clinical trials. Patients should prioritize these research-heavy centers for complex or undiagnosed immune conditions.

Patient Consensus: Patients note that San Raffaele is a top choice for primary immunodeficiencies and advanced trials. Many emphasize its collaboration with international institutions as a major factor for choosing Milan for rare disease care.

Italy offers new EMA-approved biologics like Anifrolumab for lupus and Bimekizumab for psoriatic arthritis. Targeted oral JAK inhibitors including Upadacitinib and Filgotinib are also widely available. These therapies are accessible through specialized IRCCS centers like San Raffaele and Humanitas Research Hospital in Milan.

• Lupus therapies: Anifrolumab targets Type I interferon receptors via intravenous or subcutaneous injection.
• Arthritis inhibitors: Newer oral JAK inhibitors provide non-injection alternatives for rheumatoid arthritis patients.
• Dual inhibition: Bimekizumab treats psoriatic arthritis by simultaneously blocking IL-17A and IL-17F proteins.
• Advanced research: San Raffaele pioneered the world first stem cell therapy for immune deficiencies.

Bookimed Expert Insight: Data from Milanese centers shows a high concentration of expertise in rare autoimmune conditions. Dr. Emanuele Della Torre at San Raffaele is a recognized global expert in IgG4-related diseases. Patients often find faster access to clinical trials and the latest AIFA-approved molecules at these research-heavy IRCCS institutions compared to general hospitals.

Patient Consensus: Patients note that starting documentation of previous treatment failures immediately helps speed up the approval process. Those treated in Northern Italy often report significantly shorter wait times for the newest drug listings than in Southern regions.

Allergen immunotherapy (AIT) accessibility in Italy remains highly variable due to regional reimbursement policies. The National Health System (SSN) covers grass pollen treatments for specific groups. However, patients often face full costs for other allergens like house dust mites depending on their local residence.

• Regional coverage: Tuscany and Trentino-Alto Adige provide free treatment for most common allergens.
• Wait times: Public system referrals for immunology specialists often involve 6 to 12 month waits.
• Specialist access: Major centers like San Raffaele in Milan employ board-certified allergy and immunology experts.
• Private options: Private allergists typically start immunotherapy within 2 to 4 weeks for faster access.

Bookimed Expert Insight: Patients seeking AIT should prioritize clinics with IRCCS accreditation, such as San Raffaele or San Donato. This Italian Ministry of Health certification signals a research-driven environment. These institutions often handle 300,000+ patients annually. Their high volume and academic links, featuring experts like Dr. Emanuele Della Torre, ensure access to the latest immunological protocols.

Patient Consensus: Patients note that sublingual therapy is the most convenient option for home use. Many emphasize the need to self-advocate or seek second opinions to successfully navigate the public reimbursement process.